Chicago, April 27, 2022 (GLOBE NEWSWIRE) -- According to Arizton’s latest research report, the global anti-inflammatory drugs market is expected to grow at a CAGR of 6.8% during 2022-2027. Promising investigational drugs in clinical trial pipelines and a rise in the commercialization of anti-inflammatory drugs are the key opportunities in the market. The growing use of biologics to treat inflammatory diseases is one of the major factors driving the market.
Biologics and biosimilars have revolutionized the treatment algorithm for inflammatory diseases and have markedly improved the outcome of the therapy. The biologics & biosimilars market is to reach $100 billion by 2027.
Anti-Inflammatory Drugs Market Report Scope
| REPORT ATTRIBUTES | DETAILS | |
| MARKET SIZE (2027) | $154 Billion | |
| CAGR (2022-2027) | 6.8% | |
| BASE YEAR | 2021 | |
| FORECAST YEAR | 2022-2027 | |
| LARGEST MARKET | North America | |
| FASTEST MARKET | APAC | |
| SEGMENTS COVERED | Drug class, application, route of administration, and geography | |
| REGIONS | North America, Europe, APAC, Latin America, and Middle East & Africa | |
| COUNTRIES COVERED | US, Canada, Germany, UK, France, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey South Africa, and Saudi Arabia | |
Click Here to Download the Free Sample Report
Surge in Availability of Approved Biosimilars to Treat Inflammatory Diseases
The advent of biopharmaceuticals has changed the treatment outcomes for many chronic conditions, including autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, diabetes, and cancer. Also, biopharmaceuticals have been used for the induction and remission of ulcerative colitis and Crohn's disease for nearly two decades and are effective in patients with a history of failed conventional treatments with steroids and immunomodulators. The use of biologics to treat inflammatory diseases, such as IBD, has amplified over the previous few years. The rise in incidences of various severe and complicated diseases, such as penetrating and fistulating Crohn's disease, has contributed to a surge in the use of biologics as a first-line treatment.
Key Highlights
- In 2021, North America was the major revenue contributor and accounted for 41.4% of the global anti-inflammatory drugs market and will witness the highest incremental growth during the forecast period.
- The anti-inflammatory drugs market in the US is a major contributor to the North American cardiac monitoring market sharing 93.56%.
- Biologics and biosimilars is the major contributor to the global anti-inflammatory drugs market, and it is likely to witness high incremental growth during the forecast period.
To know more click: https://www.arizton.com/market-reports/anti-inflammatory-drugs-market
Market Segmentation
Drug Class
- Biologics & Biosimilars
- NSAIDs
- Steroids
- Others
Application
- Autoimmune Diseases
- Respiratory Diseases
- Others
Route Of Administration
- Parenteral
- Oral
- Topical
- Inhalational
Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- APAC
- China
- Japan
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
Competitive Landscape
Many major vendors have acquired leading companies with a comprehensive product portfolio of anti-inflammatory drugs to strengthen their market value and emerge as top players. Key vendors have also been investing in R&D initiatives to concentrate on diversifying product portfolios and expanding their global presence. Several waves of mergers and acquisitions are expected to continue as they can generate economies of scale, force companies to reconsider their organizational efficiency, and to a certain extent, increase the chances of potential blockbusters reaching the market. Further mergers may also contribute to redefining the competitive intensity in certain therapeutic areas, and even eliminate certain competing products.
Key Companies Profiles
- AbbVi
- Amgen
- Biogen
- Bristol Myers Squibb
- Eli Lilly & Company
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
Explore our healthcare lifesciences profile to know more about the industry.
Click Here to Download the Free Sample Report
Read some of the top-selling reports:
- IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026
- U.S. OTC Drugs Market - Industry Outlook & Forecast 2021-2026
- Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026
- Immunoglobulins Market - Global Outlook & Forecast 2021-2026
About Arizton:
Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Call: +1-312-235-2040
+1 302 469 0707
